Alex Gold, MD has over 20 years of extensive experience in development and commercialization of new therapeutics in the pharmaceutical and biotech industries. His track record includes five products approved and commercialized globally and three companies acquired. He has expertise in operational leadership at the C-suite level, including global clinical development, regulatory approvals, fundraising, corporate strategy, commercialization, academic collaboration and medical affairs.
Dr. Gold is currently Chief Medical Officer at a stealth biotech company in California. He previously served as Chief Medical Officer and President at Sanifit Therapeutics, which was acquired by Vifor Pharma and subsequently CSL, Ltd. Prior to that Dr. Gold was SVP and Head of Clinical Development at Portola Pharmaceuticals, where he built and led the clinical and medical affairs organization, delivering two approved regulatory submissions, AndeXa® and BevyxXa. (Portola was subsequently acquired by Alexion). Prior to Portola Dr. Gold was Head of Clinical Development at Reata Pharmaceuticals after eleven years at AstraZeneca, where his last position was as Executive Director and Development Brand Leader for CRESTOR®, ONGLYZA® and BRILINTA®. In these roles, he led teams and activities related to development, approval and commercialization of these products. During his career, he held multiple leadership positions in various therapeutic areas, including hematology, thrombosis, cardiometabolic, nephrology, inflammation, and oncology.
Dr. Gold is Adjunct Professor at Stanford University School of Medicine and previously was a visiting lecturer at Penn Institute for Translational Medicine and Therapeutics (ITMAT). He has authored numerous publications in peer-reviewed journals, including New England Journal of Medicine, Circulation, and American Heart Journal. He has presented and led symposia on diverse topics related to the science and development of innovative medicines. Dr. Gold received his MD at Harvard Medical School and his BA at Brandeis University. He completed post-graduate medical training at Beth Israel Deaconess Medical Center, Boston in internal medicine, cardiology and clinical research. He also received executive training at Wharton.
How do I contact Alexander M. Gold?
Has Alexander M. Gold been buying or selling shares of Mineralys Therapeutics?
Over the course of the past ninety days, Alexander M. Gold has sold $1,576,112.76 in Mineralys Therapeutics stock. Most recently, Alexander M. Gold sold 12,742 shares of the business's stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $46.50, for a transaction totalling $592,503.00. Learn More on Alexander M. Gold's trading history.
Who are Mineralys Therapeutics' active insiders?
Are insiders buying or selling shares of Mineralys Therapeutics?
In the last twelve months, Mineralys Therapeutics insiders bought shares 4 times. They purchased a total of 3,661,001 shares worth more than $70,599,973.50. In the last twelve months, insiders at the sold shares 25 times. They sold a total of 1,673,513 shares worth more than $65,594,244.11. The most recent insider tranaction occured on November, 20th when Director Brian Taylor Slingsby sold 1,000,000 shares worth more than $43,350,000.00. Insiders at Mineralys Therapeutics own 25.6% of the company.
Learn More about insider trades at Mineralys Therapeutics. Information on this page was last updated on 11/20/2025.
